Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion criteria:~* Adult patients, ≥ 18 years of age~* Active rheumatoid arthritis~* Inadequate treatment with any DMARD other than methotrexate~Exclusion criteria:~* Rheumatic autoimmune disease or inflammatory joint disease other than rheumatoid arthritis~* Concurrent treatment with any DMARD other than methotrexate~* Previous treatment with any cell-depleting therapies~* Any surgical procedure in past 12 weeks, or planned within 48 weeks after baseline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received matching placebo:~* on Day 15 of Cycle 1 (Participants who were administered OCR 400 mg on Day 1 of a Cycle 1 in combination with Methotrexate)~* on both Days 1 and Day 15 of Cycle 1 (Participants who were randomized to the Placebo + Methotrexate group)
- Ocrelizumab 400mg (Type: EXPERIMENTAL): Participants received Ocrelizumab 400mg in combination with Methotrexate on Day 1, Cycle 1.
- Ocrelizumab 200mg (Type: EXPERIMENTAL): Participants received Ocrelizumab 200 mg in combination with Methotrexate on Day 1 and Day 15, Cycle 1.
- Ocrelizumab 200mg/ Ocrelizumab 200mg (Type: EXPERIMENTAL): Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2
- Ocrelizumab 200mg/ Ocrelizumab 400mg (Type: EXPERIMENTAL): Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive a single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2
- Ocrelizumab 400mg/ Ocrelizumab 400mg (Type: EXPERIMENTAL): Participants who received single 400mg infusions of Ocrelizumab + Methotraxate during Cycle 1 received a infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2
- Placebo/ Ocrelizumab 200mg (Type: EXPERIMENTAL): Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2
- Placebo/ Ocrelizumab 400mg (Type: EXPERIMENTAL): Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2

Based on this trial design, predict the completion outcome and termination type (if applicable).